I'll answer the first question briefly.
The tax incentives are a factor. I believe that there is really a way to improve the situation by increasing tax incentives for pharmaceutical companies. I believe that we were very innovative in retaining the human capital of these companies.
As we previously mentioned, several companies shut down in Canada. However, the people who had been trained at these companies ended up in the broader university ecosystem, mainly at the IRIC Drug Discovery Unit, where we are based. The unit is made up of approximately 70 highly qualified people who came from the pharmaceutical companies. They are therefore able to contribute to the development of university research as it moves towards the next value inflection point.